Transforming growth factor-beta inhibits cellular adenylate cyclase activity in cultured human arterial endothelial cells.
Stimulation of human arterial endothelial cells with heparin-binding growth factor-1 (HBGF-1) resulted in a 40% to 60% increase in the cellular adenylate cyclase activity and intracellular cAMP content. The stimulatory effect of HBGF-1 was effectively suppressed by pretreating the cells with transforming growth factor-beta (TGF-beta), an endothelial cell growth inhibitor. The inhibition of the adenylate cyclase activity precedes growth inhibition by at least 24 h. The half maximal inhibitory dose was calculated to be 0.2 ng/ml for the inhibition of both cyclase activity and cell growth. The possible role of the adenylate cyclase suppression in growth inhibition by TGF-beta is discussed.
Mioh
H
H
W. Alton Jones Cell Science Center Inc., Lake Placid, New York 12946.
Chen
J K
JK
D000067956:Adenylyl Cyclase Inhibitors; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000201:enzymology; D016220:Fibroblast Growth Factor 1; D006131:Growth Inhibitors; D006133:Growth Substances / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D006494:Heparin Antagonists; D006801:Humans; D066298:In Vitro Techniques; D015291:Transforming Growth Factors / Q000494:pharmacology*
D000067956:Adenylyl Cyclase Inhibitors; D006131:Growth Inhibitors; D006133:Growth Substances; D006494:Heparin Antagonists; D016220:Fibroblast Growth Factor 1; D015291:Transforming Growth Factors; D006493:Heparin; D000242:Cyclic AMP